Europe Sarcopenia Treatment Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 1,033,968.39 |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché européen du traitement de la sarcopénie, par type de traitement (médicaments, vitamines/ compléments alimentaires et autres), type (sarcopénie primaire et sarcopénie secondaire), stades (pré-sarcopénie, sarcopénie et sarcopénie sévère), voie d'administration (orale, injectable et autres), sexe (homme et femme), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et taille du marché du traitement de la sarcopénie en Europe
Le principal facteur à l’origine de la croissance du marché européen du traitement de la sarcopénie est la prévalence croissante de cette maladie. En outre, la sensibilisation croissante à la sarcopénie et à ses effets néfastes sur la santé est un autre facteur clé de la croissance du marché. Des facteurs liés au mode de vie, tels qu’une mauvaise alimentation et un comportement sédentaire, influencent également le marché. Cependant, l’absence de diagnostic standardisé et le coût élevé du traitement et de l’intervention devraient freiner la croissance du marché.
Data Bridge Market Research analyse que le marché européen du traitement de la sarcopénie devrait atteindre la valeur de 1 033 968,39 milliers USD d'ici 2030, à un TCAC de 4,6 % au cours de la période de prévision.
Ce rapport de marché couvre également en profondeur l’analyse des prix et les avancées technologiques.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en milliers de dollars américains, volumes en unités, prix en dollars américains |
|
Segments couverts |
Type de traitement (médicaments, vitamines/compléments alimentaires et autres), type (sarcopénie primaire et sarcopénie secondaire), stades (pré-sarcopénie, sarcopénie et sarcopénie sévère), voie d'administration (orale, injectable et autres), sexe (homme et femme), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) |
|
Pays couverts |
Allemagne, France, Royaume-Uni, Italie, Espagne, Russie, Turquie, Belgique, Pays-Bas, Suisse, Danemark, Norvège, Suède, Pologne, Finlande et reste de l'Europe |
|
Acteurs du marché couverts |
Abbott., Nestlé Health Science (une filiale de Nestlé SA), Novartis AG, Sanofi, Haleon Group of Companies, BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India, Healing Pharma India Pvt. Ltd., OPKO Health, Inc., NMD PHARMA A/S, Regeneron Pharmaceuticals Inc., Biophytis, ARMGO Pharma, Inc. Rejuvenate Biomed NV. Et entre autres |
Définition du marché
Le traitement de la sarcopénie fait référence au paysage commercial lié aux produits et services visant à prévenir, gérer ou traiter la sarcopénie, une maladie progressive liée à l’âge caractérisée par la perte de masse, de force et de fonction des muscles squelettiques, commençant généralement vers l’âge de 30 ans et s’accélérant après l’âge de 60 ans.
Sarcopenia has significant consequences on an individual's overall health and quality of life. There is a corresponding decline in muscle strength and endurance, making everyday tasks more challenging and increasing the risk of falls and fractures as muscle mass decreases. In addition, sarcopenia can lead to metabolic changes, insulin resistance, and an increased likelihood of obesity.
Europe Sarcopenia Treatment Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Prevalence of Sarcopenia
Sarcopenia is a medical condition characterized by the loss of muscle mass, strength, and function, particularly in older adults. They naturally experience a gradual loss of muscle mass and function, which predisposes them to sarcopenia as people age. The number of individuals at risk of developing sarcopenia is increasing steadily with the world's population aging. This demographic shift directly drives the demand for sarcopenia treatment options. The increasing prevalence of the condition means that more individuals require diagnosis and treatment, creating a larger patient pool for the sarcopenia treatment market.
People are living longer lives with advances in healthcare and medicine. However, as individuals age, they are more likely to develop sarcopenia. This longer life expectancy contributes to the overall prevalence of the condition. Chronic illnesses such as diabetes, cardiovascular disease, and cancer can lead to muscle loss and contribute to the development of sarcopenia. The increasing incidence of these conditions has a direct impact on the rising prevalence of sarcopenia.
The demand for effective interventions to prevent or manage sarcopenia is expected to increase, fostering research, development, and innovation in the field of sarcopenia treatment as the world's population continues to age, which is expected to drive market growth.
- Growing Awareness of Sarcopenia and its Detrimental Effects on Health
The growing awareness of sarcopenia and its detrimental effects on health is a significant development in the field of healthcare and aging. There has been a significant increase in research and publications related to sarcopenia. Scientific studies, medical journals, and publications have provided healthcare professionals with valuable information about the condition's prevalence, diagnosis, and consequences. Medical schools and training programs have incorporated sarcopenia into their curricula. This ensures that healthcare professionals, including doctors, nurses, and physical therapists, receive education about sarcopenia, its risk factors, and management strategies.
Opportunity
Strategic Initiatives by the Key Market Players
The sarcopenia treatment market is witnessing substantial growth as it is a progressive age-related condition characterized by the loss of muscle mass, strength, and function. It is a significant health concern, particularly among the elderly population, as it can lead to decreased mobility, increased risk of falls and fractures, and a decline in overall quality of life due to which key market players are proactively taking strategic initiatives for product development. Thus, opening up opportunities for market expansion and advancement.
Strategic initiative includes collaborations and partnerships with research institutions, healthcare organizations, and academic centers. Market players can leverage their knowledge and resources to accelerate the development and commercialization of sarcopenia treatments by collaborating with experts in the field. Such collaborations facilitate knowledge exchange, access to patient populations for clinical trials, and the pooling of expertise to drive innovation in the market.
Restraint / Challenge
Lack of Standardized Diagnostics
The absence of standardized diagnostic criteria may result in delayed diagnosis or missed cases of sarcopenia. Healthcare professionals may not routinely screen for the condition, especially in adults, which can hinder early intervention and treatment initiation. Without a standardized diagnosis, healthcare providers may use different criteria and methods to identify sarcopenia. This inconsistency can lead to variations in the reported prevalence of sarcopenia and the number of diagnosed cases, making it challenging to assess the true market size and demand for treatments.
Sarcopenia is a multifaceted condition that can affect individuals differently based on factors such as age, gender, and comorbidities. Patient groups may be heterogeneous, making it challenging to conduct clinical trials and research to evaluate treatment efficacy accurately without standardized diagnostic criteria. Clinical trials for sarcopenia treatments may use different diagnostic criteria, making it challenging to compare the results of various studies. This lack of standardization can hinder the development and approval of new treatments by regulatory agencies.
Recent Developments
- In February 2023, Nestlé Health Science announced that they entered into a research collaboration with EraCal Therapeutics, to identify novel nutraceuticals relevant to controlling food intake. This will increase the company's product portfolio and overall revenue.
- In November 2022, Abbott announced that it has been awarded by the Consumer Technology Association (CTA) with three CES 2023 innovation awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.
Europe Sarcopenia Treatment Market Scope
The Europe sarcopenia treatment market is segmented into seven notable segments such as treatment type, type, stages, route of administration, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Vitamin/Dietary Supplements
- Medications
- Others
On the basis of treatment type, the market is segmented into medications, vitamin/dietary supplements, and others.
Type
- Primary Sarcopenia
- Secondary Sarcopenia
On the basis of type the market is segmented into primary sarcopenia and secondary sarcopenia.
Stages
- Pre-Sarcopenia
- Sarcopenia
- Severe Sarcopenia
On the basis of stages, the market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia.
Route of Administration
- Oral
- Injectable
- Others
On the basis of route of administration the market is segmented into oral, injectable, and others.
Gender
- Male
- Female
On the basis of gender the market is segmented into male and female.
End User
- Hospitals
- Speciality Clinics
- Home Healthcare
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics, home healthcare, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel the market is segmented into direct tender, retail sales, and others.
Europe Sarcopenia Treatment Market Regional Analysis/Insights
The Europe sarcopenia treatment market is analyzed and market size insights and trends are provided by country, treatment type, type, stages, route of administration, gender, end user, and distribution channel.
The countries covered in this market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest of Europe.
Germany is expected to dominate the Europe sarcopenia treatment market owing to the higher level of investments by various manufacturers and increasing demand for pharmaceutical products manufacturing in the region.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Sarcopenia Treatment Market Share Analysis
Le paysage concurrentiel du marché européen du traitement de la sarcopénie fournit des détails sur le concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence régionale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination de l'application. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.
Certains des principaux acteurs du marché opérant sur le marché européen du traitement de la sarcopénie sont Abbott., Nestlé Health Science (une filiale de Nestlé SA), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India, Healing Pharma India Pvt. Ltd. et entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE SARCOPENIA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT
5 EUROPE SARCOPENIA TREATMENT MARKET: REGULATIONS
5.1 REGULATIONS IN U.S.
5.2 REGULATIONS IN EUROPE
5.3 REGULATIONS IN AUSTRALIA
5.4 REGULATIONS IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF SARCOPENIA
6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH
6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR
6.2 RESTRAINTS
6.2.1 LACK OF STANDARDIZED DIAGNOSIS
6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
6.4 CHALLENGES
6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT
6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL
7 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 VITAMIN/DIETARY SUPPLEMENTS
7.2.1 VITAMIN SUPPLEMENTS
7.2.2 PROTEIN SUPPLEMENTS
7.2.3 FATTY ACID SUPPLEMENTS
7.2.4 CREATINE
7.2.5 WHEY PROTEINS
7.2.6 L-CARNITINE
7.2.7 SOY
7.2.8 BETA-ALANINE
7.2.9 OSTARINE
7.2.10 COLLAGEN PEPTIDES
7.2.11 LIGANDROL
7.2.12 BRANCH-CHAIN AMINO ACIDS
7.2.13 HYDROXYMETHYLBUTYRATE (HMB)
7.2.14 MEDIUM CHAIN TRIGLYCERIDES
7.2.15 OTHERS
7.3 MEDICATIONS
7.3.1 OFF LABEL DRUGS
7.3.2 EMERGING DRUGS
7.3.2.1 ACE INHIBITORS
7.3.2.2 APPETITE STIMULANTS
7.3.2.3 ORAL ANTIDIABETIC DRUGS
7.3.2.4 OTHERS
7.4 OTHERS
8 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 PRIMARY SARCOPENIA
8.2.1 VITAMIN/DIETARY SUPPLEMENTS
8.2.2 MEDICATIONS
8.2.3 OTHERS
8.3 SECONDARY SARCOPENIA
8.3.1 VITAMIN/DIETARY SUPPLEMENTS
8.3.2 MEDICATIONS
8.3.3 OTHERS
9 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES
9.1 OVERVIEW
9.2 PRE-SARCOPENIA
9.3 SARCOPENIA
9.4 SEVERE SARCOPENIA
10 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 INJECTABLES
10.4 OTHERS
11 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PUBLIC
12.2.2 PRIVATE
12.3 SPECIALTY CLINICS
12.4 HOME HEALTHCARE
12.5 OTHERS
13 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACIES
13.3.2 ONLINE PHARMACIES
13.3.3 OTHERS
13.4 OTHERS
14 EUROPE SARCOPENIA TREATMENT MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 FRANCE
14.1.3 U.K.
14.1.4 ITALY
14.1.5 SPAIN
14.1.6 RUSSIA
14.1.7 TURKEY
14.1.8 BELGIUM
14.1.9 NETHERLANDS
14.1.10 SWITZERLAND
14.1.11 DENMARK
14.1.12 NORWAY
14.1.13 SWEDEN
14.1.14 POLAND
14.1.15 FINLAND
14.1.16 REST OF EUROPE
15 EUROPE SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ABBOTT
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 NOVARTIS AG
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 PIPELINE PORTFOLIO
17.3.6 RECENT DEVELOPMENT
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 HALEON GROUP OF COMPANIES.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ASTAREAL CO., LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 BASF SE
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BIOGEN SA
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 BIOTHRIVE SCIENCES
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 DSM
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 FERMENTA BIOTECH LIMITED
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 HEALING PHARMA INDIA PVT. LTD.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 METAGENICS
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 THE VITAMIN COMPANY INDIA
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 WELLONA PHARMA
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ARMGO PHARMA, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 PIPELINE PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 BIOPHYTIS
17.17.1 COMPANY SNAPSHOT
17.17.2 PIPELINE PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 DYSTROGEN THERAPEUTICS CORP
17.18.1 COMPANY SNAPSHOT
17.18.2 PIPELINE PORTFOLIO
17.18.3 RECENT DEVELOPMENT
17.19 IMMUNOFORGE INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PIPELINE PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MYMD PHARMACEUTICALS
17.20.1 COMPANY SNAPSHOT
17.20.2 PIPELINE PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 NMD PHARMA A/S
17.21.1 COMPANY SNAPSHOT
17.21.2 PIPELINE PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 ONCOCROSS CO., LTD.
17.22.1 COMPANY SNAPSHOT
17.22.2 PIPELINE PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 OPKO HEALTH, INC.
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PIPELINE PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 REGENERON PHARMACEUTICALS INC.
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 PIPELINE PORTFOLIO
17.24.4 RECENT DEVELOPMENT
17.25 REJUVENATE BIOMED NV
17.25.1 COMPANY SNAPSHOT
17.25.2 PIPELINE PORTFOLIO
17.25.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 CURRENT STATUS OF THE DEVELOPMENT OF DRUG FOR SARCOPENIA TREATMENT
TABLE 2 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 6 EUROPE MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 EUROPE OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 9 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 11 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 13 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 15 EUROPE PRE-SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 16 EUROPE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 17 EUROPE SEVERE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 19 EUROPE ORAL IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 20 EUROPE INJECTABLES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 22 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 23 EUROPE MALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 24 EUROPE FEMALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 25 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 26 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 27 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 EUROPE SPECIALTY CLINICS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 29 EUROPE HOME HEALTHCARE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 30 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 31 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 32 EUROPE DIRECT TENDER IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 33 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 34 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 35 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 36 EUROPE SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 37 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 38 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 40 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 41 EUROPE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 42 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 46 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 47 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 48 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 49 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 51 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 52 GERMANY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 GERMANY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 56 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 57 GERMANY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 GERMANY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 59 GERMANY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 GERMANY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 GERMANY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 62 GERMANY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 63 GERMANY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 64 GERMANY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 65 GERMANY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 66 GERMANY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 67 GERMANY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 68 FRANCE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 FRANCE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 70 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 71 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 72 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 73 FRANCE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 74 FRANCE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 75 FRANCE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 76 FRANCE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 FRANCE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 78 FRANCE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 79 FRANCE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 80 FRANCE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 81 FRANCE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 FRANCE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 83 FRANCE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 84 U.K. SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 U.K. MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 88 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 89 U.K. VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 90 U.K. SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 91 U.K. PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 92 U.K. SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 U.K. SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 94 U.K. SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 95 U.K. SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 96 U.K. SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 97 U.K. HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 U.K. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 99 U.K. RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 100 ITALY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 ITALY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 103 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 104 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 105 ITALY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 106 ITALY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 ITALY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 108 ITALY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 109 ITALY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 110 ITALY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 111 ITALY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 112 ITALY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 113 ITALY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 ITALY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 115 ITALY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 116 SPAIN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 117 SPAIN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 120 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 121 SPAIN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 122 SPAIN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 SPAIN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 SPAIN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 SPAIN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 126 SPAIN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 127 SPAIN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 128 SPAIN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 129 SPAIN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 130 SPAIN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 131 SPAIN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 132 RUSSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 RUSSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 134 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 135 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 136 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 137 RUSSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 138 RUSSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 RUSSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 RUSSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 RUSSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 142 RUSSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 143 RUSSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 144 RUSSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 145 RUSSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 146 RUSSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 147 RUSSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 148 TURKEY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 149 TURKEY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 152 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 153 TURKEY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 154 TURKEY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 TURKEY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 TURKEY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 TURKEY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 158 TURKEY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 159 TURKEY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 160 TURKEY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 161 TURKEY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 TURKEY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 163 TURKEY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 164 BELGIUM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 165 BELGIUM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 166 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 167 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 168 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 169 BELGIUM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 170 BELGIUM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 BELGIUM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 BELGIUM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 173 BELGIUM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 174 BELGIUM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 175 BELGIUM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 176 BELGIUM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 177 BELGIUM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 BELGIUM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 179 BELGIUM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 180 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 NETHERLANDS MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 184 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 185 NETHERLANDS VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 186 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 187 NETHERLANDS PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 NETHERLANDS SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 189 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 190 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 191 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 192 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 193 NETHERLANDS HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 195 NETHERLANDS RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 196 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 SWIZTERLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 198 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 200 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 201 SWIZTERLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 202 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 203 SWIZTERLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 204 SWIZTERLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 206 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 207 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 208 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 209 SWIZTERLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 210 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 211 SWIZTERLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 212 DENMARK SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 DENMARK MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 216 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 217 DENMARK VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 218 DENMARK SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 219 DENMARK PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 DENMARK SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 DENMARK SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 222 DENMARK SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 223 DENMARK SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 224 DENMARK SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 225 DENMARK HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 DENMARK SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 227 DENMARK RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 228 NORWAY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 229 NORWAY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 230 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 232 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 233 NORWAY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 234 NORWAY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 NORWAY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 236 NORWAY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 237 NORWAY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 238 NORWAY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 239 NORWAY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 240 NORWAY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 241 NORWAY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 242 NORWAY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 243 NORWAY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 244 SWEDEN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 SWEDEN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 248 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 249 SWEDEN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 SWEDEN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 251 SWEDEN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 SWEDEN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 253 SWEDEN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 254 SWEDEN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 255 SWEDEN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 256 SWEDEN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 257 SWEDEN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 258 SWEDEN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 259 POLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 260 POLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 261 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 262 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 263 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 264 POLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 265 POLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 266 POLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 267 POLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 268 POLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 269 POLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 270 POLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 271 POLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 272 POLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 273 POLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 274 POLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 275 FINLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 FINLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 279 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 280 FINLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 281 FINLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 282 FINLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 FINLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 284 FINLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 285 FINLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 286 FINLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 287 FINLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 288 FINLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 289 FINLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 290 FINLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 291 REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE SARCOPENIA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE SARCOPENIA TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 EUROPE SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION
FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030
FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PRECLINICAL MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE SARCOPENIA TREATMENT MARKET
FIGURE 14 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022
FIGURE 15 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2022
FIGURE 19 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 20 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 21 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2022
FIGURE 23 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND)
FIGURE 24 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 25 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 26 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 27 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030)
FIGURE 28 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030)
FIGURE 29 EUROPE SARCOPENIA TREATMENT MARKET: LIFELINE CURVE
FIGURE 30 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2022
FIGURE 31 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 32 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 33 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 34 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2022
FIGURE 35 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 36 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 40 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 41 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 42 EUROPE SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 43 EUROPE SARCOPENIA TREATMENT MARKETSTRUCTURAL HEALTH MONITORING MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
